Seattle Genetics + Astellas collaborate with Merck Inc., to evaluate enfortumab vedotin in combination with Keytruda to treat metastatic urothelial cancer.
Seattle Genetics, Inc.and Astellas Pharma Inc. announced a clinical collaboration agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to evaluate the combination of Seattle Genetics� and Astellas� antibody-drug conjugate (ADC) enfortumab vedotin and Merck�s anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with previously untreated metastatic urothelial cancer.
Under the terms of the agreement, the three companies will conduct and fund a global, registrational phase III clinical trial to be led by Seattle Genetics. The trial will be designed to evaluate the efficacy of the combination of enfortumab vedotin and pembrolizumab in patients with previously untreated locally advanced or metastatic urothelial cancer. The companies are working in consultation with regulatory authorities to finalize the trial design and currently plan to initiate the trial in the first half of 2020.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.